Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed full pipeline small index

Heroin Dependence: full-pipeline trial registry

A small indexed set (12 trials) with no open enrollment listed right now.

Corpus placement: #1,429 of 28,707 conditions by registered trial count.

12 US clinical trials · none currently recruiting · #1,429 of 28,707 conditions by registered trial count

Heroin Dependence: 12 US clinical trials tracked, none currently recruiting.

Heroin Dependence is the subject of 12 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 5 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute on Drug Abuse (NIDA), running 5 of these trials.

Enrollment posture brief

Registry condition heroin-dependence

OPEN 0 | RECR 0% | LATE 5 | EARLY 7 | RANK #1429 | SPON 5

Nearest open-share peer: Adenocarcinoma of the Gastroesophageal Junction (0% recruiting · 8 trials)

Acute Myeloid Leukemia in Re41.7%Adenocarcinoma of the Rectum41.7%Adherence, Patient16.7%Accelerated Phase Chronic My0%Heroin Dependence (this)0%
Open-enrollment share among volume-matched conditions near Heroin Dependence

Heroin Dependence has no open enrollment in this registry pull (12 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Heroin Dependence on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Heroin Dependence is recruiting below its size-band peers.

    0 of 12 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Heroin Dependence research.

    National Institute on Drug Abuse (NIDA) accounts for 5 of 12 trials (41.7%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Typical Heroin Dependence enrolment sits around 60 participants.

    Median target enrolment is 60 among the 9 trials that report a genuine target (sentinel values excluded). 5 of those (55.6%) plan for fewer than 100 participants.

  4. Heroin Dependence research is mostly interventional.

    12 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 26Phase 34Phase 41

Indexed trials (enrollment closed)

12 total, page 1 of 1

COMPLETED Phase 3 341 participants

Buprenorphine/Naloxone Versus Clonidine for Outpatient Opiate Detoxification - 1

University of California, Los Angeles

NCT00032968

COMPLETED Phase 2 142 participants

Treatment of Opioid/Heroin Dependence: Comparison of Three Medication Dosing Regimens

National Institute on Drug Abuse (NIDA)

NCT00218127

COMPLETED Phase 2 140 participants

The Efficacy of Methadyl Acetate (LAAM) and Contingency Management Procedures for Treating Dual Opioid and Cocaine Abuse - 1

National Institute on Drug Abuse (NIDA)

NCT00158288

COMPLETED Phase 2 107 participants

Directly Administered HIV Therapy in Methadone Clinics

Johns Hopkins University

NCT00279110

COMPLETED Phase 3 60 participants

Behavioral Naltrexone Therapy for Promoting Adherence to Oral Naltrexone vs Extended Release Injectable Depot Naltrexone

New York State Psychiatric Institute

NCT00577408

COMPLETED Phase 2 36 participants

Study of Computer-Based Treatment for Drug Dependence

Yale University

NCT01315184

COMPLETED Phase 3 27 participants

Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone

New York State Psychiatric Institute

NCT01760473

COMPLETED Phase 2 12 participants

Opiate Dependence: Combined Naltrexone/Behavior Therapy - 1

New York State Psychiatric Institute

NCT00238914

COMPLETED Phase 2 8 participants

A Laboratory Model for Heroin Abuse Medications - 8

New York State Psychiatric Institute

NCT00000273

COMPLETED Phase 1

Buprenorphine and Naloxone Combination Study - 10

National Institute on Drug Abuse (NIDA)

NCT00015288

COMPLETED Phase 4

Effects of Buspirone in Opiate Withdrawal

National Institute on Drug Abuse (NIDA)

NCT00326235

COMPLETED Phase 3

Study Comparing Liquid and Tablet Buprenorphine Formulations - 5

National Institute on Drug Abuse (NIDA)

NCT00000302

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 6
Phase 3 4
Phase 4 1

Named interventions

Most-linked intervention names on Heroin Dependence records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Buprenorphine/naloxone Drug
2 trials
Recovery Line Support System Behavioral
1 trials
opiates Drug
1 trials
LAAM Behavioral
1 trials
Oral Naltrexone Drug
1 trials
depot naltrexone Drug
1 trials
Compliance Enhancement (CE) Behavioral
1 trials
Behavioral Naltrexone Therapy (BNT) Behavioral
1 trials

US sites by state

Facility locations filed on Heroin Dependence trials. A trial with sites in several states counts in each.

New York 7 trials
Connecticut 2 trials
California 2 trials
Texas 1 trials
Oregon 1 trials
New Jersey 1 trials
Maryland 1 trials
Indiana 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Heroin Dependence page

12 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Heroin Dependence condition card totals 12 registered trials; most-linked intervention Buprenorphine/naloxone; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.